A New Standard of Care

Introducing

QSTM^®

Quantifiable Soft Tissue Manipulation

Terry Loghmani, PT, Ph.D.

OUR FOUNDER'S JOURNEY

The idea for Quantifiable Soft Tissue Manipulation (QSTM) originated from Terry Loghmani, PT, Ph.D., Associate Professor Department of Physical Therapy / School of Health and Human Sciences, Indiana University in Indianapolis, and Director of the Applied Regenerative Medicine Lab. Dr. Lohgmani is a Physical Therapist, Orthopedic Manual Therapist, Massage Therapist, and an Instrument-Assisted Soft Tissue Mobilization (IASTM) expert whose research has helped advance the manual therapies field.

As a foundational trainer with The Graston Technique (IASTM), Dr. Loghmani witnessed the variability in the therapy tools used by the hands of different therapists as well as patient outcomes. She set out to develop a tool that would consistently measure the force, angle, cadence, and area for therapists in real-time.

Jennifer Holmes, CEO

OUR CEO

Jennifer Holmes joined Precision Care Technology as Chief Executive Officer, a Boomerang Ventures portfolio company. She brings 30 years of senior executive experience in the medical device and MedTech sector. Throughout her career, Jennifer has consistently accelerated revenue growth, led operations and commercialization, spearheaded succession planning, and managed complex change initiatives. Recently, as CEO of Rehab Boost, Inc., she successfully guided the company through a merger and acquisition, selling its assets and intellectual property to MedBridge, a Brentwood Associates (PE firm) portfolio company.

Jennifer’s extensive leadership experience includes roles such as Board Chairman, President and CEO, Senior Vice President of Enterprise Sales, Vice President of National Accounts, and various management positions at prominent companies, including Boston Scientific, Guidant Corporation (Abbott), Spectranetics (Philips), MedAssets (Vizient), Central Logic (ABOUT Healthcare), and Rehab Boost, Inc (MEDBRIDGE).

READ FULL BIO

Several notable achievements were launching the first enterprise sales initiative targeting C-suite executives at large healthcare systems, driving $42M in top-line growth for an $800M public healthcare supply chain (GPO), revenue cycle management, workforce labor optimization, and consulting organization. Additionally, Jennifer turned around U.S. sales operations at a mid-cap public medical device company, increasing revenue from $65M to $110M in three years. Over her career, she has successfully launched hundreds of new medical devices, secured multi-million-dollar contracts with major Integrated Delivery Networks (IDNs), and achieved double-digit growth at several early-stage startups. Her expertise lies in executing commercial operating plans, aligning sales and marketing strategies, leading turnarounds, and building high-performing teams.

Jennifer has experience raising early-stage capital, Seed, Seed A, and Series C growth funding rounds. She has won numerous accolades as CEO of a SaaS healthcare IT company, where she was recognized as a Fierce Innovation Award Finalist for developing a comprehensive care coordination solution while at Central Logic. Under her leadership, the company was named one of Modern Healthcare’s Top 100 Best Places to Work. She has been featured in Becker’s Hospital Review as one of the Top 17 “Female Health IT Company CEOs to Know” and was a finalist for the Women Tech Council’s Utah Tech Awards.

Jennifer holds a Bachelor of Science in Sports Medicine and Exercise Physiology from Indiana University, Bloomington, Indiana.

OVERVIEW

QSTM^® IS SOFT TISSUE PHYSICAL THERAPY REIMAGINED

Precision Care Technologies’ QSTM transforms the subjective into objective through quantified, measurable outcomes.

Injuries in the U.S.

0 M

Soft Tissue Manual Therapy

0 %

Trillion In Costs

$ 1.15 T

There are 63 million work, sport, and other injuries in the U.S., representing $1.28T in costs, supported by Physical Therapists, Chiropractors, Athletic Trainers, and other rehab specialists, according to research.

There are millions of physical therapy-related visits per year, of which an estimated 70-80% include soft tissue manual therapy. However, soft tissue manual therapy is mostly subjective, without sufficient measurable ways to capture treatment history, process, and outcomes.

This can lead to variability in care, discrepancies in patient experience, and little objective clinical data to support outcomes improvements and the development of a consistent standard of care.

01. Our Mission

02. Our Vision

To transform the future of soft tissue therapy, bridging technology and expertise to create a world where every patient receives exceptional, data-driven care.

THE SCIENCE BEHIND QTSM™

INNOVATIVE TECHNOLOGIES

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.